MIM
MCRB icon

Monashee Investment Management’s Seres Therapeutics MCRB Stock Holding History

Monashee Investment Management’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-5,000
Closed -$322K – 160
2019
Q2 		$322K Buy
+5,000
New +$475K 0.08% 132

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Monashee Investment Management's MCRB Position: Q3 2019 in Review

Monashee Investment Management sold out of Seres Therapeutics (MCRB) in Q3 2019, closing a stake of 5,000 shares — an estimated $322K sold.

Monashee Investment Management first reported a position in MCRB in Q2 2019 and held it in 1 quarter. The position peaked at $322K in Q2 2019. 77 funds tracked by Wall St. Rank hold MCRB as of Q3 2019.

  • Monashee Investment Management reported no remaining Seres Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Monashee Investment Management sold 5,000 Seres Therapeutics shares in Q3 2019, an estimated $322K.
  • Monashee Investment Management first reported a position in Seres Therapeutics in Q2 2019 and held it in 1 quarter.
  • Monashee Investment Management's Seres Therapeutics position peaked at $322K in Q2 2019.
  • 77 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2019.

Based on Monashee Investment Management's 13F filing for Q3 2019, filed 12 Nov 2019.